A breast cancer charity has welcomed the approval of a new drug to treat women with a particularly aggressive form of the disease, describing the new medication as giving "precious hope" for more lives to be saved in the long term.
The Scottish Medicines Consortium (SMC) has recommended pembrolizumab be prescribed to patients with advanced or early stage triple negative breast cancer at high risk of recurrence, as part of other treatments including chemotherapy and surgery.
In addition, the advisory body cleared the use of five other medicines this week including one which will be used to treat patients with an extremely rare disorder affecting how the body accumulates and stores fat.
